FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159772021> ?p ?o ?g. }

• W3159772021 abstract "Abstract Introduction: Ertugliflozin (ERTU), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is approved as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus (T2DM). Aim: As a pre-specified sub-study of the Phase 3 VERTIS CV trial (NCT01986881), the efficacy and safety of ERTU were assessed in patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) inadequately controlled with metformin and sulfonylurea (SU). Methods: Patients with T2DM, established ASCVD, and HbA1c 7.0–10.5% on stable metformin (≥1500 mg/day) and SU doses as defined per protocol were randomized to once-daily ERTU (5 mg or 15 mg) or placebo. The primary sub-study objectives were to assess the effect of ERTU on HbA1c compared with placebo and to evaluate safety and tolerability during 18-week follow-up. Key secondary endpoints included proportion of patients achieving HbA1c &lt;7%, fasting plasma glucose (FPG), body weight, and systolic blood pressure. Changes from baseline at Week 18 for continuous efficacy endpoints were assessed using a constrained longitudinal data analysis model. Results: Of the 8246 patients enrolled in the VERTIS CV trial, 330 patients were eligible for this sub-study (ERTU 5 mg, n=100; ERTU 15 mg, n=113; placebo, n=117). Patients had a mean (SD) age of 63.2 (8.4) years, T2DM duration 11.4 (7.4) years, estimated glomerular filtration rate 83.5 (17.8) mL/min/1.73 m2, and HbA1c 8.3% (1.0) (67.4 [10.6] mmol/mol). At Week 18, ERTU 5 mg and 15 mg were each associated with a significantly greater least squares mean (95% CI) HbA1c reduction from baseline versus placebo; the placebo-adjusted differences for ERTU 5 mg and 15 mg were –0.7% (–0.9, –0.4) and –0.8% (–1.0, –0.5), respectively (P&lt;0.001). A higher proportion of patients in each ERTU group achieved HbA1c &lt;7% relative to placebo (P&lt;0.001). ERTU significantly reduced FPG and body weight (P&lt;0.001, for each dose versus placebo), but not systolic blood pressure. Adverse events were reported in 48.0%, 54.9%, and 47.0% of patients in the ERTU 5 mg, 15 mg, and placebo groups, respectively. Genital mycotic infections were experienced by significantly higher proportions of male patients who received ERTU 5 mg and 15 mg (4.2% and 4.8%, respectively) versus placebo (0.0%; P≤0.05) and by a numerically, but not significantly, higher proportion of female patients who received ERTU 15 mg (10.3%) compared with placebo (3.8%) (P=0.36). The incidences of symptomatic hypoglycemia were 11.0% (5 mg), 12.4% (15 mg), and 7.7% (placebo), and of severe hypoglycemia 2.0% (5 mg), 1.8% (15 mg), and 0.9% (placebo). Conclusion: Among patients with T2DM and ASCVD, ERTU (5 mg and 15 mg) added to metformin and SU for 18 weeks improved glycemic control (HbA1c and FPG) and reduced body weight, and was generally well tolerated with a safety profile consistent with the SGLT2 inhibitor class." @default.
• W3159772021 created "2021-05-10" @default.
• W3159772021 creator A5021841408 @default.
• W3159772021 creator A5026935251 @default.
• W3159772021 creator A5043791621 @default.
• W3159772021 creator A5051174907 @default.
• W3159772021 creator A5066554764 @default.
• W3159772021 creator A5068186050 @default.
• W3159772021 creator A5079194052 @default.
• W3159772021 creator A5079665496 @default.
• W3159772021 date "2021-05-01" @default.
• W3159772021 modified "2023-09-27" @default.
• W3159772021 title "Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease Treated With Metformin and Sulfonylurea" @default.
• W3159772021 doi "https://doi.org/10.1210/jendso/bvab048.676" @default.
• W3159772021 hasPublicationYear "2021" @default.
• W3159772021 type Work @default.
• W3159772021 sameAs 3159772021 @default.
• W3159772021 citedByCount "0" @default.
• W3159772021 crossrefType "journal-article" @default.
• W3159772021 hasAuthorship W3159772021A5021841408 @default.
• W3159772021 hasAuthorship W3159772021A5026935251 @default.
• W3159772021 hasAuthorship W3159772021A5043791621 @default.
• W3159772021 hasAuthorship W3159772021A5051174907 @default.
• W3159772021 hasAuthorship W3159772021A5066554764 @default.
• W3159772021 hasAuthorship W3159772021A5068186050 @default.
• W3159772021 hasAuthorship W3159772021A5079194052 @default.
• W3159772021 hasAuthorship W3159772021A5079665496 @default.
• W3159772021 hasBestOaLocation W31597720211 @default.
• W3159772021 hasConcept C126322002 @default.
• W3159772021 hasConcept C134018914 @default.
• W3159772021 hasConcept C142724271 @default.
• W3159772021 hasConcept C197934379 @default.
• W3159772021 hasConcept C203092338 @default.
• W3159772021 hasConcept C204787440 @default.
• W3159772021 hasConcept C27081682 @default.
• W3159772021 hasConcept C2777180221 @default.
• W3159772021 hasConcept C2778375690 @default.
• W3159772021 hasConcept C2778854520 @default.
• W3159772021 hasConcept C2779306644 @default.
• W3159772021 hasConcept C2780323712 @default.
• W3159772021 hasConcept C2780473172 @default.
• W3159772021 hasConcept C2910068830 @default.
• W3159772021 hasConcept C535046627 @default.
• W3159772021 hasConcept C555293320 @default.
• W3159772021 hasConcept C71924100 @default.
• W3159772021 hasConcept C84393581 @default.
• W3159772021 hasConcept C90924648 @default.
• W3159772021 hasConceptScore W3159772021C126322002 @default.
• W3159772021 hasConceptScore W3159772021C134018914 @default.
• W3159772021 hasConceptScore W3159772021C142724271 @default.
• W3159772021 hasConceptScore W3159772021C197934379 @default.
• W3159772021 hasConceptScore W3159772021C203092338 @default.
• W3159772021 hasConceptScore W3159772021C204787440 @default.
• W3159772021 hasConceptScore W3159772021C27081682 @default.
• W3159772021 hasConceptScore W3159772021C2777180221 @default.
• W3159772021 hasConceptScore W3159772021C2778375690 @default.
• W3159772021 hasConceptScore W3159772021C2778854520 @default.
• W3159772021 hasConceptScore W3159772021C2779306644 @default.
• W3159772021 hasConceptScore W3159772021C2780323712 @default.
• W3159772021 hasConceptScore W3159772021C2780473172 @default.
• W3159772021 hasConceptScore W3159772021C2910068830 @default.
• W3159772021 hasConceptScore W3159772021C535046627 @default.
• W3159772021 hasConceptScore W3159772021C555293320 @default.
• W3159772021 hasConceptScore W3159772021C71924100 @default.
• W3159772021 hasConceptScore W3159772021C84393581 @default.
• W3159772021 hasConceptScore W3159772021C90924648 @default.
• W3159772021 hasLocation W31597720211 @default.
• W3159772021 hasOpenAccess W3159772021 @default.
• W3159772021 hasPrimaryLocation W31597720211 @default.
• W3159772021 hasRelatedWork W10195258 @default.
• W3159772021 hasRelatedWork W1372849 @default.
• W3159772021 hasRelatedWork W15647580 @default.
• W3159772021 hasRelatedWork W1739382 @default.
• W3159772021 hasRelatedWork W20349743 @default.
• W3159772021 hasRelatedWork W2474835 @default.
• W3159772021 hasRelatedWork W288983 @default.
• W3159772021 hasRelatedWork W6387984 @default.
• W3159772021 hasRelatedWork W8744681 @default.
• W3159772021 hasRelatedWork W16973082 @default.
• W3159772021 isParatext "false" @default.
• W3159772021 isRetracted "false" @default.
• W3159772021 magId "3159772021" @default.
• W3159772021 workType "article" @default.